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electroimmunotransfer blot (EITB) assay for cysticercosis
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ABSTRACT
Diagnosis of the parasitic infection cysticercosis is usually conﬁrmed by serological assays. The
electroimmunotransfer blot (EITB) for cysticercosis is a sensitive and speciﬁc assay, which uses six
glycoprotein antigens on a strip to detect antibodies to Taenia solium cysticerci. Although the appearance
of bands at any of these six sites is considered to be a positive result, a growing body of evidence
suggests that the presence of a single 50-kDa band in this assay may not indicate infection. An audit of
984 samples tested over a 3-year period showed that only two (15.4%) of 13 samples with a single 50-
kDa band were associated with a diagnosis of cysticercosis. Possible reasons for this include technical
problems, cross-reactivity with other parasites or other diseases, or the presence of a non-speciﬁc band.
The results suggest that the ﬁnding of a single 50-kDa band should be interpreted with caution.
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INTRODUCTION
Cysticercosis is a parasitic infection caused by the
larval stage of the pork tapeworm Taenia solium.
Following human ingestion of eggs, the parasites
migrate to striated muscle, brain, liver and other
tissues, where they encyst. Symptoms depend on
the localisation of the cysts. Of greatest concern is
encystation in the brain, which causes the poten-
tially life-threatening illness neurocysticercosis.
This may be asymptomatic or may present with
seizures, focal neurological deﬁcit, or other signs
of a space-occupying lesion.
Cysticercosis often presents a diagnostic chal-
lenge to the clinician faced with its non-speciﬁc
signs and symptoms. Radiological abnormalities
are present frequently, but may not be sufﬁ-
ciently speciﬁc to make a deﬁnitive diagnosis.
Demonstration of cysticerci in affected tissue
samples is the reference standard for diagnosis,
but requires invasive sampling at an early stage
of investigation. Stool microscopy may demon-
strate tapeworm eggs and proglottids, but does
not prove a diagnosis of cysticercosis, being
merely an indication of carriage (taeniasis).
Therefore, serological assays are used commonly
to conﬁrm the diagnosis before the initiation of
treatment [1,2].
The electroimmunotransfer blot (EITB) is the
most widely used of the serological assays for
cysticercosis. This assay uses six glycoprotein
antigens on a strip to detect antibodies to Taenia
solium cysticerci. Early work suggested that the
EITB has 98% sensitivity and 100% speciﬁcity
[3]. In practice, the sensitivity is reduced in
cases with low numbers of cysts or with only
calciﬁed lesions [4,5]. In addition, although the
appearance of bands at any of these six sites has
been considered to be a positive result, a
growing body of evidence suggests that the
presence of a single 50-kDa band in this assay
does not always correlate well with the clinical
ﬁndings, raising concerns that a single 50-kDa
band might not necessarily indicate a diagnosis
of cysticercosis [3,6]. The present study des-
cribes the results of an audit of EITB results, in
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which laboratory ﬁndings were compared with
ﬁnal diagnoses.
MATERIALS AND METHODS
The cysticercosis EITB (Immunetics, Cambridge, MA, USA) [3]
is used mainly on serum samples, but CSF samples may be
tested if required (this is an unlicensed indication, but has been
validated previously [3–5,7]). The kit uses six glycoprotein
antigens, derived from T. solium proteins, of molecular size 50,
42–39, 41, 24, 18 and 14 kDa. These antigens are separated and
blotted on strips of nitrocellulose. Serum or CSF specimens are
incubated with the strips, which are then washed to remove
unbound antibodies. Binding is visualised by reaction with
goat anti-human IgG-alkaline phosphatase conjugate, followed
by 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetra-
zolium substrate. The strip is then compared with a control
strip. Bands should align closely with the control bands, but
may not be identical. At the Hospital for Tropical Diseases
(HTD, London, UK), the strips were processed and read by
highly trained and experienced staff, and were cross-checked
by a second staff member. Interpretation of results and clinical
advice were offered. The presence of any of these bands was
reported as a positive result. Any other band pattern, or the
absence of bands, was reported as a negative result.
All EITBs undertaken at the HTD between October 1999
and February 2003 were included in the audit. A log of all
results had been kept, as had the dried test strips. The log was
reviewed and all positive results were entered into an Excel
database. The hospital notes for each positive case, where
available, were reviewed to ascertain the ﬁnal diagnosis. If the
samples had been referred from another centre, a standard
letter was sent to the referring laboratory to request that the
ﬁnal diagnosis be made available. A second letter was sent
1 month later to non-responders.
RESULTS
In total, 927 sera were tested at HTD during the
period studied, of which 835 were negative and
92 were positive (i.e., at least one positive band in
the EITB). In addition, 57 CSF samples were
tested, of which 50 were negative and seven were
positive. The number of positive bands in each
sample was ascertained, and diagnoses were
established from hospital notes or from letters
from the referring laboratory. The diagnosis was
not available in every case. Of 92 positive cases, a
reply or diagnosis was available for 48 (52.2%)
cases. Of these, 28 (58.3%) cases had a diagnosis
of cysticercosis. Cases for which a diagnosis was
not available all involved referrals of serum
and ⁄ or CSF samples from other laboratories
which failed to respond to the two written
requests for information. The diagnoses were
compared to the laboratory ﬁndings (number of
bands), as summarised in Table 1. The positivity
rate per band was calculated (Table 2). Cases
where only a single band was positive were
analysed by size of band vs. diagnosis (Table 3).
Single band positivity occurred most com-
monly with the 50-kDa band, and most of these
cases did not have a ﬁnal diagnosis of cysticerco-
sis. Of the 13 patients with a single positive
50-kDa band from serum, only two (15.4%) had
cysticercosis. Of the remaining 11 patients, one
had cerebral tuberculosis, one had metastatic lung
cancer, one had systemic lupus erythematosus
(SLE), one had an angiolipoma, three were infec-
ted with other parasites (one mixed infection with
Schistosoma and Trichuris, one with Enterobius, and
one with Armillifer armillatus), and four had no
deﬁnite diagnosis.
Table 3. Cysticercosis vs. size of band for single-band
positives
Band
size (kDa)
No. of
patients
No. of patients
positive for
cysticercosis
50 13 2
42 ⁄ 39 1 1
24 1 1
21 1 0
18 0 0
14 2 0
18 4
Table 2. Positivity rate for each band, grouped according
to clinical diagnosis
Band
(kDa)
Cysticercosis:
number of
positives
Other diagnosis:
number of positives
50 23 ⁄ 28 (82%) 16 ⁄ 20 (80%)
42 ⁄ 39 21 ⁄ 28 (75%) 2 ⁄ 20 (10%)
24 21 ⁄ 28 (75%) 3 ⁄ 20 (15%)
21 8 ⁄ 28 (29%) 3 ⁄ 20 (15%)
18 3 ⁄ 28 (11%) 0 ⁄ 20 (0%)
14 9 ⁄ 28 (32%) 3 ⁄ 20 (15%)
Table 1. Number of positive bands in electroimmuno-
transfer blot (EITB) assays compared with clinical diagno-
ses
No. of
positive
bands
Positive
cases
(n)
Diagnosis
available
(n)
Diagnosis of
cysticercosis
(n)
% of known diagnoses
where the diagnosis
was cysticercosis
1 34 18 4 22
2 16 10 5 50
3 25 12 11 92
4 10 3 3 100
5 5 4 4 100
6 2 1 1 100
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DISCUSSION
A single positive 50-kDa band was associated
with a diagnosis of cysticercosis in only two of 13
cases. All serum or CSF samples reported in this
retrospective audit were from patients for whom
cysticercosis was being considered as a diagnosis
by the clinical team, and who were thus regarded
as having been potentially exposed to the risk of
infection. There is no reason to expect that
clinically undetected active or previous cysticer-
cosis should be more common in this group of
patients than in the other cases audited, and the
remaining 11 cases must therefore be regarded as
false-positives. This false-positive rate of 11 ⁄ 13
(84.6%) is clearly unacceptably high, but the
reason for this is unclear. It seems unlikely that
reading errors alone could be responsible; each
strip was read by two experienced members of
the laboratory staff and was compared with a
control strip. Furthermore, reading errors alone
would not explain why it is predominantly the 50-
kDa band which gives false-positive results.
It may be that the populations used to develop
the test differed from those presenting to the
diagnostic laboratory. Tsang et al. [3] developed
the EITB at the CDC, and much of the original
ﬁeldwork took place in Peru [8,9]. The Peruvian
studies involved a relatively homogeneous pop-
ulation, whereas the diagnostic laboratory at HTD
deals with patients from worldwide locations
which may represent different parasite burdens.
It is well-known that the parasite exhibits anti-
genic variation, and it has been suggested that
puriﬁed parasite antigens should be derived from
pools of cysts obtained from different regions of
endemicity worldwide [10]. However, this would
require further development and investment in
the assay.
An alternative explanation may involve cross-
reaction between the EITB antigens and other
parasites. In the group of patients with a false-
positive 50-kDa band, three had infections with
unrelated parasites (A. armillatus, Enterobius
vermicularis and mixed Schistosoma ⁄Trichuris).
However, the original study [3] did not ﬁnd
any cross-reaction between the EITB and schisto-
somiasis. There are no published data concerning
cross-reactivity with Trichuris, Enterobius or
Armillifer, but cross-reaction seems unlikely
because these parasites are genetically very dif-
ferent from Taenia. In the present study, one
patient with a single 14-kDa band had tapeworm
segments (species unspeciﬁed) in the stool, and
one patient with bands at 50 kDa and 42 ⁄ 39 kDa
had Taenia saginata (beef tapeworm) (results not
shown). It can probably be accepted that the EITB
cross-reacts with T. saginata, because of the
genetic and antigenic similarity between the two
Taenia species.
A further possibility involves cross-reaction
between the EITB and other diseases. Although,
intuitively, this seems less likely, cross-reaction is
possible, particularly in diseases which stimulate
the humoral immune response. One case in which
a single 50-kDa band was observed concerned a
patient with SLE. Little is known about use of the
EITB in patients with SLE, and this is an area that
could be evaluated further. Another patient with
a single 50-kDa band had metastatic lung cancer.
Kojic and White [6] described a false-positive 50-
kDa band in a patient with high-grade cerebral
neoplasm. Again, further evaluation of any poss-
ible correlation between false-positive EITB
results and neoplasia is needed.
Diagnoses other than cysticercosis were made
by the clinical teams concerned before this
retrospective audit. There is no reason to expect
that the criteria used for these conditions were
different for any of the subgroups, or that there
was a bias towards alternative diagnoses for
patients with a single 50-kDa band. It must also
be considered whether the apparent false-positive
results may have been caused by previous or
current cysticercosis outside the nervous system.
This possibility is difﬁcult to exclude completely,
even by whole body magnetic resonance imaging,
but the chance of this occurring should not be any
greater in patients with a single 50-kDa band than
in patients with other band patterns where no
cysticerci could be visualised.
The speciﬁcity of the EITB is derived from the
relative purity and physical separation of the
glycoprotein bands on the strip, which should
allow differentiation between genuine antigen-
antibody binding and non-speciﬁc binding. How-
ever, non-speciﬁc binding is recognised, and the
originators of the EITB described a potentially
confusing non-speciﬁc band, dubbed a ‘bogus
band’, which can appear slightly above the 50-
kDa band [3]. The bogus band may appear
sharper than the genuine 50-kDa band, but its
position near or at the expected location of the
true 50-kDa band, makes it very difﬁcult to
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distinguish between true and ‘bogus’ bands.
Tsang et al. [3] elected to retain the 50-kDa
glycoprotein in the strip, despite this ﬁnding,
because sera from two patients with conﬁrmed
cysticercosis reacted only with the 50-kDa band,
so that omission of the 50-kDa band from the
panel might result in occasional missed diagno-
ses. The present audit conﬁrmed this possibility,
as two of the study patients with cysticercosis had
only a single positive 50-kDa band.
The EITB has improved the laboratory diag-
nosis of cysticercosis signiﬁcantly, and remains
the best option for serological diagnosis, but its
interpretation requires skill and experience.
While the presence of a single 50-kDa band
can indicate cysticercosis, the present audit of
results shows that this ﬁnding is much more
common for patients in whom no evidence of
cysticercosis can be found. Therefore, the pres-
ence of a single 50-kDa band must be inter-
preted with particular caution. Clinicians should
seek early specialist advice regarding the inter-
pretation of test results, and relevant clinical,
epidemiological and radiological information
should be used to guide diagnosis and further
management. The recent cloning of the 50-kDa
glycoprotein gene should lead to signiﬁcantly
improved performance of the EITB. In a pre-
liminary study of the recombinant 50-kDa pro-
tein in a western blot, Hancock et al. [11]
reported 100% speciﬁcity for cysticercosis and
90% sensitivity for cysticercosis-positive serum
samples that reacted with the 50-kDa compo-
nent of the lentil lectin-puriﬁed glycoprotein
antigens used in the EITB assay available
currently.
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